Lunai Bioworks (NASDAQ:LNAI) Stock Rating Upgraded by Wall Street Zen

Lunai Bioworks (NASDAQ:LNAI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings initiated coverage on Lunai Bioworks in a research note on Wednesday, October 8th. They set a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Lunai Bioworks Trading Up 1.9%

Shares of LNAI opened at $1.05 on Friday. The company’s 50-day moving average is $1.12. The firm has a market capitalization of $24.60 million, a PE ratio of -15.00 and a beta of 0.37. Lunai Bioworks has a 1-year low of $0.81 and a 1-year high of $17.50.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.13 EPS for the quarter.

Institutional Investors Weigh In On Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC bought a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks as of its most recent SEC filing. Institutional investors own 71.41% of the company’s stock.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.